Expert Interview

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Investigating the potential of two oral JAK inhibitors, Rinvoq (upadacitinib) from Abbvie and Povorcitinib (INCB54707) from Incyte Bio as treatments for non-segmental vitiligo.

Ticker(s): ABBV, INCY

Who's the expert?

Institution: Indiana University School of Medicine

Chair and associate professor of dermatlogy at Indiana University School of Medicine.
Currently manages 100 patients with vitligo.
Previously served as Vice-Chair for Research and Education at Tufts Medical Center, focusing on clinical trials for inflammatory disorders of the skin.

Interview Goal

This call will focus on the current standard of care and the potential of two oral JAK inhibitors, Rinvoq (upadacitinib) from Abbvie and Povorcitinib (INCB54707) from Incyte Bio for the treatment of non-segmental vitiligo. There will also be an analysis of the data from the recent phase 2 clinical trials evaluating Rinvoq (upadacitinib) and Povorcitinib (INCB54707) in patients with non-segmental vitiligo.

Are You Interested In These Questions?

Yes! Sign me up for FREE
so I can learn more Yes.
LOGIN!

Click Here to Access
This Project

Slingshot Insights Explained

JOIN FOR FREE TODAY

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

Click Here to Access
This Project

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.